MYGN logo

MYGN Myriad Genetics, Inc.

NASDAQ · Medical - Diagnostics & Research · Healthcare

$5.54
+0.01 (+0.18%)

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovari…

Market Cap: $531.41Mwww.myriad.com

Price

$3.26-31.37%
$2.86$4.01$5.16$6.31
Apr 30Aug 7

Social Signal Score

52
5d
—
30d
57
3 mentions
+0.0%
60d
50
5 mentions
+0.0%
90d
49
8 mentions
+0.0%
news: 8

Analyst Ratings

37 analysts
Holdconsensus
Strong Buy 0Buy 8Hold 22Sell 7Strong Sell 0
Avg price target$5.42-2.2%
Low $3.6Median $5High $8
Current Consensus

Revenue

$202.70M+3.16%
$0.00$72.27M$144.53M$216.80M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$0.01
$0.01–$0.01
8 analysts
FY2026
$-0.70-7246% YoY
$-0.72–$-0.69
4 analysts
FY2027
$-0.69
$-0.70–$-0.67
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Samraat S. Raha
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
2,700
Beta
1.61
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-0.95
www.myriad.com